Investigating the role of oral supplementation of Branched Chain Amino Acid in Critically ill patients with Traumatic injury RSPL2.1

Abstract

Background: Traumatic brain injury stands for important global health burden. There are no therapies proven to improve the outcome of patients with TBI in ICU. Branched Chain Amino Acid oral therapy is a nutrition intervention that may improve recovery. Aim of work: To determine the effect of BCAA oral therapy supplementation to ICU patients after TBI. To find the relation between oral administration of BCAA and the degree of healing in TBI patients via measurement of reduction in inflammatory stress mediators levels and to assess the impact of BCAA oral therapy on patient outcome. Objective: Improve the Quality of Life of critically ill patients in ICU. Patients and methods: 52 participants of both sexes and age are between 20 to 80 years diagnosed with Traumatic brain Injury was recruited. Participants randomized [1:1] received either the intervention of oral Branched chain amino acids or control. The intervention commenced in ICU. A standard clinical data sheet included Demographic characteristics of study population, clinical history, comorbidities and baseline measures including SOFA, APACHE, GSC, CRP and IL-6. Follow up sheet designed for outcome measurements for patients in ICU (7-10 days). Outcome measurements included measurements of SOFA, APACHE, GSC, CRP and IL-6. Results: It revealed that control and intervention groups baselines are comparable regarding age (46.5 vs 43.2), gender (F: 6 vs 5, M: 20 vs 21), GCS (12.4 vs 12.5), APACHE (8.4vs 8.7), SOFA (3.11 vs 2.65), CRP (81.58 vs 112.46 mg/L) and IL-6 (89.7 vs 72.3 Pg/ml). Statistical analysis of outcome measurements for control group regarding CRP is 125.56 mg/L and IL-6 is 45.7pg/ml while outcome measurements for intervention group regarding CRP is 69.25 mg/L and IL-6 is 17pg/ml. Conclusion: According to statistical analysis performed there is a significant difference between intervention and control (P-value < 0.05) regarding the impact of IL-6 and CRP mean levels.